First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm, multicenter phase II study aimed at evaluating the
efficacy and safety of Disitamab Vedotin in Combination With Tirelizumab and S-1 as
first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal
junction adenocarcinoma.